Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro
The commercial team is on board and ready to market the first FDA-approved RNAi therapeutic patisiran for hereditary transthyretin-mediated amyloidosis.
You may also be interested in...
Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren’t far behind.
Givosiran was approved by the US FDA for the treatment of acute hepatic porphyria, a rare generic blood disorder, nearly three months ahead of the action date.
The recent US FDA approval of three drugs – Alnylam’s Onpattro, Ionis’ Tegsedi and Pfizer’s tafamidis – in transthyretin-mediated amyloidosis means more opportunities to increase education and improve diagnosis in this rare disease, Alnylam CEO John Maraganore tells Scrip.